Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Hold” at StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

A number of other research analysts have also recently issued reports on ATNM. Maxim Group lifted their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $25.72.

Actinium Pharmaceuticals Price Performance

Shares of ATNM opened at $8.96 on Friday. The stock has a market cap of $266.83 million, a price-to-earnings ratio of -5.24 and a beta of 0.08. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. As a group, sell-side analysts anticipate that Actinium Pharmaceuticals will post -1.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC bought a new position in Actinium Pharmaceuticals in the 1st quarter valued at $78,000. Creative Financial Designs Inc. ADV raised its position in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the last quarter. Finally, Brandywine Global Investment Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter valued at $1,033,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.